このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Kiniksa Pharmaceuticals 将来の成長
Future 基準チェック /46
Kiniksa Pharmaceuticalsは、44.1%と18.7%でそれぞれ年率44.1%で利益と収益が成長すると予測される一方、EPSはgrowで43.2%年率。
主要情報
44.1%
収益成長率
43.2%
EPS成長率
| Biotechs 収益成長 | 24.7% |
| 収益成長率 | 18.7% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 21 Jun 2024 |
今後の成長に関する最新情報
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01Recent updates
Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Nov 30Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
Nov 16業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | 655 | 48 | 86 | 65 | 4 |
| 12/31/2025 | 536 | 42 | 81 | 60 | 6 |
| 12/31/2024 | 389 | -8 | 23 | 12 | 6 |
| 3/31/2024 | 302 | 9 | 21 | 22 | N/A |
| 12/31/2023 | 270 | 14 | 13 | 13 | N/A |
| 9/30/2023 | 249 | -7 | -3 | -3 | N/A |
| 6/30/2023 | 281 | 231 | 42 | 42 | N/A |
| 3/31/2023 | 236 | 196 | 38 | 38 | N/A |
| 12/31/2022 | 220 | 183 | 6 | 6 | N/A |
| 9/30/2022 | 177 | 143 | -2 | -2 | N/A |
| 6/30/2022 | 90 | -112 | -92 | -92 | N/A |
| 3/31/2022 | 71 | -134 | -123 | -123 | N/A |
| 12/31/2021 | 39 | -158 | -147 | -126 | N/A |
| 9/30/2021 | 20 | -175 | -169 | -149 | N/A |
| 6/30/2021 | 8 | -189 | -175 | -154 | N/A |
| 3/31/2021 | N/A | -184 | -165 | -145 | N/A |
| 12/31/2020 | N/A | -161 | -137 | -137 | N/A |
| 9/30/2020 | N/A | -140 | -122 | -120 | N/A |
| 6/30/2020 | N/A | -123 | -117 | -114 | N/A |
| 3/31/2020 | N/A | -122 | -129 | -127 | N/A |
| 12/31/2019 | N/A | -162 | -162 | -158 | N/A |
| 9/30/2019 | N/A | -173 | -167 | -162 | N/A |
| 6/30/2019 | N/A | -170 | -159 | -153 | N/A |
| 3/31/2019 | N/A | -153 | -136 | -129 | N/A |
| 12/31/2018 | N/A | -103 | -86 | -81 | N/A |
| 9/30/2018 | N/A | -93 | -78 | -77 | N/A |
| 6/30/2018 | N/A | -85 | -68 | -67 | N/A |
| 3/31/2018 | N/A | -76 | -60 | -60 | N/A |
| 12/31/2017 | N/A | -65 | N/A | -50 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: KNSAの予測収益成長率 (年 間44.1% ) は 貯蓄率 ( 2.4% ) を上回っています。
収益対市場: KNSAの収益 ( 44.1% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。
高成長収益: KNSAの収益は今後 3 年間で 大幅に 増加すると予想されています。
収益対市場: KNSAの収益 ( 18.7% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: KNSAの収益 ( 18.7% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: KNSAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です